Spongiotic psoriasiform dermatitis with dual features of eczema and psoriasis: Janus kinase inhibition as a potential therapeutic option
Clinical and Experimental Dermatology · 25.11.2025 · 50 (12) · 2431-2438
DOI: 10.1093/ced/llaf336 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 28.07.2025. Verfasst von Wenjie Cheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Psoriasis, Janus Kinase Inhibitors, Eczema. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: funds from the National Nature Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Background
Psoriasis (PSO) and eczema are inflammatory skin disorders with distinct immune mechanisms. PSO is mainly driven by T helper (Th)17 immune responses, while eczema, notably atopic dermatitis (AD), is Th2 mediated. Spongiotic psoriasiform dermatitis (SD/PSO), a hybrid phenotype of both conditions, lacks precise immunophenotypic characterization and specific treatment strategies. Existing studies have shown that some patients with SD/PSO exhibit a poor response to conventional and single T-cell axis-targeted therapies (such as Th2/Th17 inhibitors), suggesting cross-activation of immune pathways, which urgently requires more targeted intervention strategies.
Objective
To characterize the immunological and differentiation profiles of SD/PSO, clarify its differences from classical PSO and AD, and identify alternative therapies for conventional therapy-resistant patients.
Methods
Four patients with SD/PSO were evaluated. Histopathological analysis and tyramide signal amplification-based multiplex immunofluorescence assay were performed to assess immune profiles and keratinocyte differentiation profiles.
Results
In four patients with SD/PSO, conventional therapies showed inadequate response. Three patients experienced lesion exacerbation with interleukin (IL)-17A inhibitors. Immunomarker analysis revealed mixed Th17/Th2 activation: Th17 markers (IL-17A, IL-23, IL-36A/G) were comparably elevated to PSO, while IL-4 levels matched AD and IL-13 exhibited moderate-level expression (between PSO and AD). SD/PSO lesions exhibited PSO-like epidermal differentiation with Janus kinase–signal transducer and activator of transcription (JAK-STAT) hyperactivation and JAK inhibitor treatment induced significant clinical improvement.
Conclusions
SD/PSO represents a mixed AD-PSO immunophenotype with PSO-like differentiation patterns, characterized by coactivated Th17/Th2 pathways and JAK-STAT hyperactivation. JAK inhibitors effectively treat patients with SD/PSO by suppressing multi-T-cell axis-targeted inflammatory signals and blocking epidermal hyperproliferation, establishing JAK-STAT inhibition as a targeted strategy. Larger studies are needed to validate results and explore combination therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
ORCID-Profile: Yumeng Wang
Förderung
- funds from the National Nature Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Cheng, W., Pan, C., Xu, Q., Li, J., Wang, X., Wang, Y., Sun, P., Chen, X., Yang, J., Yao, Z., & Li, C. (2025). Spongiotic psoriasiform dermatitis with dual features of eczema and psoriasis: Janus kinase inhibition as a potential therapeutic option. Clinical and Experimental Dermatology, 50(12), 2431-2438. https://doi.org/10.1093/ced/llaf336
Vancouver
Cheng W, Pan C, Xu Q, Li J, Wang X, Wang Y, et al. Spongiotic psoriasiform dermatitis with dual features of eczema and psoriasis: Janus kinase inhibition as a potential therapeutic option. Clinical and Experimental Dermatology. 2025;50(12):2431-2438. doi:10.1093/ced/llaf336
BibTeX
@article{Cheng2025,
author = {Cheng, Wenjie and Pan, Chaolan and Xu, Qianyue and Li, Jiawen and Wang, Xiaoxiao and Wang, Yumeng and Sun, Peiyi and Chen, Xuanyi and Yang, Jinxiang and Yao, Zhirong and Li, Chunxiao},
title = {Spongiotic psoriasiform dermatitis with dual features of eczema and psoriasis: Janus kinase inhibition as a potential therapeutic option},
journal = {Clinical and Experimental Dermatology},
year = {2025},
volume = {50},
number = {12},
pages = {2431--2438},
doi = {10.1093/ced/llaf336}
}
EUVIMED